Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + relatlimab + rHuPH20
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Nivolumab + relatlimab + rHuPH20 is an investigational subcutaneous fixed-dose immunotherapy formulation developed by Bristol Myers Squibb. It combines nivolumab, a programmed cell death protein 1 blocking monoclonal antibody, with relatlimab, a lymphocyte activation gene 3 blocking monoclonal antibody, plus recombinant human hyaluronidase PH20 to transiently degrade subcutaneous hyaluronan and facilitate dispersion and absorption of the antibody combination. The formulation is being evaluated in melanoma, including the Phase 3 RELATIVITY-127 study in previously untreated unresectable or metastatic melanoma. ([bmsstudyconnect.com](https://www.bmsstudyconnect.com/ca/en/clinical-trials/NCT05625399.html))
- Brand names
- Opdualag
- Other names
- BMS-986213 + rHuPH20nivolumab + relatlimab fixed-dose combination subcutaneousnivolumab + relatlimab + recombinant human hyaluronidasenivolumab/relatlimab/rHuPH20
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nivolumab + relatlimab + rHuPH20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + relatlimab + rHuPH20.